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INTRODUCTION
In mouse follicular melanocytes, the switch between the
synthesis of eumelanin, the dark brown or black pigment, and
pheomelanin, the red-yellow pigment, is regulated by a -
melanocyte stimulating hormone (a -MSH) and agouti signaling
protein (ASP), respectively (Geschwind, 1966; Silvers, 1979;
Prota, 1992). The mechanism of action of a -MSH involves
binding to its specific receptor, the melanocortin 1 receptor
(MC1R), which is coded for by the extension locus (Tamate and
Takeuchi, 1984; Robbins et al., 1993; Suzuki et al., 1996). The
MC1R belongs to a family of five different G-protein-coupled
receptors with seven transmembrane domains (Chhajlani and
Wikberg, 1992; Mountjoy et al., 1992; Gantz et al., 1993a;
Gantz et al., 1993b; Roselli-Rehfuss et al., 1993; Labbé et al.,
1994). Binding of a -MSH to its receptor results in activation
of adenylate cyclase and increased intracellular cAMP levels
(Wong et al., 1974; Fuller et al., 1987; Suzuki et al., 1996).
Several mutations in the mouse Mc1r gene have been identified
and their consequences on the function of the receptor and
the pigmentary phenotype have been determined (Tamate and
Takeuchi, 1984; Robbins et al., 1993). In the recessive yellow
mouse (e/e), the yellow coat color results from a frameshift
mutation in the Mc1r gene that causes deletion of a single
nucleotide at position 549, resulting in premature termination
of the receptor after the fourth transmembrane domain (Robbins
et al., 1993). The resulting receptor is uncoupled from adenylate
cyclase, thus is incapable of signaling. In the sombre (Eso/Eso)
mouse, a point mutation results in the substitution of a leucine
residue by a proline at codon 98 in the second transmembrane
domain of the MC1R. This receptor is constitutively active and
unresponsive to a -MSH (Robbins et al., 1993).
In the mouse, dominant mutations in the agouti locus that
result in ectopic and overexpression of ASP result in a yellow
coat color, in addition to other abnormalities, the most obvious
of which are obesity and increased longitudinal growth (Yen et
al., 1994; Jones et al., 1996). Agouti signaling protein is known
to antagonize the effects of a -MSH by competing for binding to
the MC1R, and/or by inhibiting the constitutive activity of the
unbound MC1R, i.e. acting as an inverse agonist (Lu et al., 1994;
Blanchard et al., 1995; Siegrist et al., 1997; Suzuki et al., 1997).
With the cloning of the mouse and human agouti genes and the
purification of their respective products, it became feasible to
elucidate the mechanism of action of ASP (Bultman et al., 1992;
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The agouti gene codes for agouti signaling protein (ASP),
which is temporally expressed in wild-type mouse follicular
melanocytes where it induces pheomelanin synthesis.
Studies using purified full-length agouti signaling protein
has shown that it competes with a -melanocyte stimulating
hormone for binding to the melanocortin 1 receptor. We
have investigated whether ASP binds exclusively to the
melanocortin 1 receptor expressed on mouse melanocytes
in primary culture, or additionally activates a receptor that
has not been identified yet. We have compared the
responses of congenic mouse melanocytes derived from C57
BL/6J-E+/E+, e/e, or Eso/Eso mice to a -MSH and/or ASP.
E+/E+ melanocytes express the wild-type melanocortin 1
receptor, e/e melanocytes express a loss-of-function
mutation in the melanocortin 1 receptor that results in a
yellow coat color, and Eso/Eso is a mutation that causes
constitutive activation of the melanocortin 1 receptor
and renders melanocytes unresponsive to a -melanocyte
stimulating hormone. Mouse E+/E+ melanocytes, but not
e/e or Eso/Eso melanocytes, respond to agouti signaling
protein with decreased basal tyrosinase activity, and
reduction in levels of tyrosinase and tyrosinase-related
proteins 1 and 2. Only in E+/E+ melanocytes does agouti
signaling protein abrogate the stimulatory effects of a -
melanocyte stimulating hormone on cAMP formation and
tyrosinase activity. These results indicate that a functional
melanocortin 1 receptor is obligatory for the response of
mammalian melanocytes to agouti signaling protein.
Key words: Melanocortin 1 receptor, Agouti signaling protein, a -
Melanocyte stimulating hormone, Melanocytes, Eumelanin,
Pheomelanin
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Miller et al., 1993). Using mouse melanoma cells, it has been
demonstrated that mouse ASP abrogates the melanogenic effects
of a -MSH (Siegrist et al., 1996). In heterologous cells that were
transfected with the Mc1r gene, it was shown that ASP competes
with a -MSH for binding to the MC1R (Lu et al., 1994). We have
shown that in melan-a mouse melanocytes, ASP blocked the a -
MSH induced increase in cAMP formation and eumelanin
synthesis (Sakai et al., 1997). We have also reported that normal
human melanocytes responded to ASP with a reduction in basal
tyrosinase activity and abrogation of the melanogenic and
mitogenic effects of a -MSH (Suzuki et al., 1997). We found that
ASP acted as a competitive inhibitor of a -MSH binding to the
MC1R on human melanocytes and blocked the a -MSH-induced
increase in cAMP levels. So far, the physiological role of ASP
in the regulation of human pigmentation remains speculative.
A pending question is whether ASP elicits its effects on
mammalian melanocytes only by binding to the MC1R or by
additionally activating another receptor that has not been
identified yet. In the current study, we attempt to address this
question using primary melanocyte cultures established from the
skins of congenic mice that express normal or naturally
occurring mutations in the Mc1r, and comparing their responses
to ASP. The use of these melanocytes, rather than transformed
malignant melanocytes (i.e. melanoma cells), provides
conclusive evidence that expression of a normally functioning




Primary mouse melanocyte cultures were established from 1-day-old
neonatal mouse skins. Skins were incubated in 0.25% Trypsin solution
at 37° C for 90-120 minutes to allow for the separation of the epidermis
from the dermis. The dermal layers of two to three skins were placed
in a 15 ml centrifuge tube containing 5 ml growth medium, and
vortexed vigorously for 3-5 minutes to obtain a cell suspension
containing dermal hair follicles. The mouse melanocyte growth
medium consisted of MCDB 153 containing 4% heat-inactivated fetal
calf serum, 1% penicillin/streptomycin, 5 m g/ml insulin, 1 m g/ml
transferrin, 1 m g/ml vitamin E, 0.6 ng/ml human recombinant basic
fibroblast growth factor, 32 nM TPA, and 5 m M dibutyryl cAMP (all
obtained from Sigma, St Louis, MO). The resulting dermal cell
suspension was transferred to a T-25 cm2/flask, and incubated in a
humidified incubator containing 5% CO2, at 37° C. For all experiments,
melanocyte cultures in passage two or three were used.
Determination of the effects of ASP and a -MSH on
tyrosinase activity
Mouse melanocytes were deprived of dibutyryl cAMP for 2-3 days prior
to, and for the entire duration of, the experiment. Melanocytes were
plated at a density of 1.3· 105 cells per 12.5 cm2/flask and allowed to
attach for 48 hours. Subsequently, and every other day thereafter, the
medium in each flask was removed and replaced with fresh medium, and
melanocytes were treated with nothing (as control), with 1 or 10 nM a -
MSH (obtained from Sigma), with 10 nM ASP, or concomitantly with
a -MSH and ASP. Recombinant ASP was purified from conditioned
media of insect cells infected with agouti-containing baculovirus as
described previously in detail (Ollmann et al., 1998). 5 days after
treatment, 2.1 m Ci 3H-tyrosine (specific activity 52 mCi/mmol, Dupont,
NEN, Boston, MA; 0.7 m Ci/ml medium) was added to each flask for a
total of 20 hours. The medium from each flask was then transferred into
a culture tube, and duplicate 1 ml samples from each tube were assayed
for tyrosinase activity in situ, as described previously in detail (Abdel-
Malek et al., 1989). This assay is based on determining the amount of
3H2O released by the melanocytes to the medium as 3H- tyrosine is
converted to L-DOPA, a reaction catalyzed by tyrosinase, the rate-
limiting enzyme in the melanin synthetic pathway. The cell number in
each flask was counted with the aid of a Coulter Counter. Tyrosinase
activity was expressed as dpm/106 cells, and then as % of control. 
cAMP determination
The effects of ASP and/or a -MSH on cAMP formation was
determining using a radioimmunoassay as previously described
(Suzuki et al., 1996). Mouse melanocytes were plated onto 24-well
plates in the absence of dibutyryl cAMP at a density of 3 · 105
cells/well. 72 hours later, the medium in each well was replaced with
0.5 ml medium containing 0.1 mM isobutyl methylxanthine, a
phosphodiesterase inhibitor, and the appropriate treatment (1 nM a -
MSH and/or 10 nM ASP), and the cultures were incubated for 40
minutes at 37 ° C. An untreated control group was included in each
experiment. The reaction was stopped by the addition of 50 m l 1N
HCl, and the assay was performed as described previously in detail
(Suzuki et al., 1996). 
Western blot analysis for tyrosinase, tyrosinase-related
proteins 1 and 2
Mouse melanocytes were plated onto 60 mm dishes at a density of 5-
7.5· 105 cells/dish, maintained in medium devoid of dibutyryl cAMP, and
treated 72 hours later with nothing (as a control), or with 1 nM a -MSH
and/or 10 nM ASP for a total of 6 days, as described above. Cell extracts
were then prepared using RIPA buffer (150 mM NaCl, 1% NP40, 0.5%
deoxycholate, 0.1% SDS and 50 mM Tris, pH 8.0), containing the
phosphatase inhibitor Na3VO4 (10 m M), and the protease inhibitors
phenymethylsulfonyl fluoride (200 m M), aprotinin (10 m g/ml) and
leupeptin (10 m g/ml). Proteins (5 m g/lane) were loaded on 8%
polyacrylamide gels and separated by electrophoresis. The separated
proteins were then transblotted onto Immobilon-P membranes
(Millipore, Bedford, MA), and the membranes were blocked by
incubation in 5% nonfat dry milk in TBS/Tween (0.1% Tween-20 in
Tris-buffered saline). The membranes were then probed with primary
antibodies a PEP7, a PEP1 and a PEP8, which are raised against
synthetic peptides that correspond to the unique C terminus of mouse
tyrosinase, tyrosinase related protein (TRP) 1 and TRP2, respectively, at
1:1000 dilution in TBS/Tween overnight at 4° C. The membranes were
then washed with TBS/Tween three times, for ten minutes each time,
and incubated with horseradish peroxidase-conjugated anti-rabbit IgG at
a dilution of 1:1000, for 2 hours. Visualization of the respective bands
was carried out using Enhanced ChemiLuminescence (Amersham,
Arlington Heights, IL), according to the manufacturer’s instructions. 
RESULTS
Effects of ASP and/or a -MSH on tyrosinase activity
and cAMP formation in primary mouse melanocyte
cultures
In this study, we compared the responses to ASP and a -MSH
of primary cultures of mouse follicular melanocytes that were
derived from the skins of congenic 1-day-old C57 BL
6J-E+/E+, C57BL6J-e/e or C57BL6J-Eso/Eso mice. E+/E+
mouse melanocytes express a normal MC1R, while e/e mouse
melanocytes harbor a point mutation in the Mc1r gene that
results in loss of function of the MC1R due to its uncoupling
from adenylate cyclase (Tamate and Takeuchi, 1984; Robbins
et al., 1993). The Eso/Eso mice express a frameshift mutation
that renders the MC1R constitutively active and blocks its
activation by a -MSH (Robbins et al., 1993). Treatment of
E+/E+ melanocytes with either 1 or 10 nM a -MSH increased
tyrosinase activity by about 60%, while treatment with 10 nM
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ASP inhibited basal tyrosinase activity by about 70% (Fig.
1A). Concomitant treatment of these melanocytes with either
1 or 10 nM a -MSH and 10 nM ASP completely abrogated the
stimulatory effect of a -MSH and reduced tyrosinase activity
by 60% or 30% below basal level, respectively. In comparison,
similar treatment of either e/e or Eso/Eso melanocytes with a -
MSH and/or ASP had no significant effect on tyrosinase
activity (Fig. 1B,C). Our findings that ASP inhibited basal
tyrosinase activity and blocked the stimulatory effect of a -
MSH in E+/E+ melanocytes led us to investigate whether or not
ASP inhibited the a -MSH-induced increase in cAMP
formation. For that, we measured cAMP formation in E+/E+
melanocytes after treatment with 1 nM a -MSH and/or 10 nM
ASP for 40 minutes. We found that a -MSH increased
intracellular cAMP levels almost fourfold; ASP alone had no
significant effect, but reduced the a -MSH-induced increase in
cAMP levels by 56% (Table 1). However, in e/e or Eso/Eso
melanocytes, neither a -MSH nor ASP had any significant
effect on control cAMP levels (data not shown).
Comparison of the morphology of cultured E+/E+,
e/e and Eso/Eso melanocytes
The morphology of E+/E+ melanocytes was very different from
that of e/e melanocytes. The former had larger cell bodies and
were multi dendritic, while the latter were thin and bipolar
(Fig. 2A,B). Melanocytes from Eso/Eso mouse skins were
similar to e/e melanocytes in that they were also bipolar. E+/E+
melanocytes treated for 4 or 6 days with 1 nM a -MSH
exhibited extensive dendrites (Fig. 2C). On the other hand,
treatment with ASP caused these melanocytes to attain a
smaller cell body and to appear darker than control
melanocytes due to the aggregation of melanin granules in the
cytoplasm (Fig. 2D). Concomitant treatment with ASP and a -
MSH resulted in inhibition of dendrite extension and in a
morphology that was intermediate between that of control
and ASP-treated melanocytes (Fig. 2E). Such morphological
changes in response to a -MSH or ASP were not evident in
either e/e or Eso/Eso melanocytes (data not shown).
Effects of ASP and a -MSH on the protein levels of
tyrosinase, TRP1 and TRP2
Our previous studies on mouse melan-a cells and normal
human melanocytes revealed that the inhibitory effects of ASP
were associated with a decrease in the amount of tyrosinase,
and a profound reduction in the expression of TRP1 and TRP2,
as determined by western blot analysis (Sakai et al., 1997;
Suzuki et al., 1997). Here, we found that treatment of E+/E+
melanocytes with 1 nM a -MSH for 6 days increased the
amount of tyrosinase, TRP1 and TRP2, while treatment with
10 nM ASP almost abolished the expression of these three
melanogenic enzymes (Fig. 3 A-C). Concomitant treatment of
those melanocytes with ASP and a -MSH resulted in a
profound reduction of the levels of tyrosinase and TRP-1 below
Fig. 1. Comparison of the effects of ASP and/or a -MSH on
tyrosinase activity of E+/E+ (A), e/e (B) and Eso/Eso (C) mouse
melanocytes. Melanocytes were treated for a total of 6 days with
1 nM or 10 nM a -MSH, 10 nM ASP, or concomitantly with either
10 nM ASP and 1 nM a -MSH, or 10 nM ASP and 10 nM a -MSH, as
described in Materials and Methods. Tyrosinase activity is expressed
as % of control±s.e.m. (n=6 determinations/group). Similar results
were obtained in two independent experiments.
Table 1. cAMP levels of C57BL/6J-E+/E+ mouse
melanocytes after treatment with ASP and/or a -MSH
cAMP/ml % of control
(pmoles±s.e.m.) ±s.e.m.
Control 2.16±0.14 100±6
a -MSH (1 nM) 8.40±0.34 389±16
ASP (10 nM) 2.79±0.28 129±13
a -MSH + ASP 3.69±0.11 171±5
Melanocytes were plated at a density of 3 · 105 cells/well in 24-well plates.
48 hours later, melanocytes were treated for 40 minutes with 0 (control),
1 nM a -MSH, 10 nM ASP, or both a -MSH and ASP. cAMP levels were
determined by radioimmunoassay, as described in Materials and Methods.
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the levels of control untreated melanocytes (Fig. 3A,B). In
contrast, e/e melanocytes responded to a -MSH with a slight
increase, and to ASP with minimal reduction, in the levels of
tyrosinase, TRP1 and TRP2. Eso/Eso melanocytes did not
respond to a -MSH and/or ASP with any alteration of the levels
of tyrosinase, TRP1 or TRP2. 
DISCUSSION
The purification of the mouse agouti gene product, ASP, has
allowed the investigation of the mechanism(s) by which ASP
signals and antagonizes the effects of a -MSH on target cells
(Bultman et al., 1992; Miller et al., 1993). That a -MSH induces
eumelanin synthesis while the expression of ASP switches to
pheomelanin synthesis in mouse follicular melanocytes has
JOURNAL OF CELL SCIENCE 114 (5)
Fig. 3. Effect of ASP and/or a -MSH on the protein levels of the
melanogenic enzymes tyrosinase (A), TRP1 (B), and TRP2 (C) in
E+/E+, e/e, Eso/Eso melanocytes. Western blot analysis was carried
out on lysates of the above three types of melanocytes that were
treated with 0 (control), 1 nM a -MSH, 10 nM ASP, or 1 nM a -MSH
and 10 nM ASP for a total of 6 days, as described in Materials and
Methods. This experiment was repeated three times with similar
results.
Fig. 2. Morphology of e/e melanocytes in comparison with that of control, a -MSH- or ASP-treated E+/E+ mouse melanocytes. (A) Control e/e
melanocytes. E+/E+ melanocytes were treated with 0 (control; B), 1 nM a -MSH (C),10 nM ASP (D), or concomitantly with 1 nM a -MSH and
10 nM ASP (E) for 6 days. Photographs were taken at the same magnification. 
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been recognized for decades (Geschwind, 1966; Silvers, 1979).
Loss-of-function mutations in the mouse Mc1r gene, as in e/e
mice, or gain-of-function mutations in the agouti gene result in
a similar pigmentary phenotype, namely yellow coat color
(Tamate and Takeuchi, 1984; Robbins et al., 1993; Yen et al.,
1994). These observations led to a number of speculations about
the mechanism of action of ASP, particularly about the nature
of the receptor(s) it binds. Several studies have provided
evidence that ASP acts as a competitive inhibitor of a -MSH
binding to the MC1R (Lu et al., 1994; Blanchard et al., 1995;
Siegrist et al., 1997; Suzuki et al., 1997). It has also been
proposed that ASP acts as an inverse agonist of the MC1R, and
results in MC1R desensitization (Siegrist et al., 1997; Suzuki
et al., 1997). Recently, we obtained data that showed that
ASP downregulates Mc1r mRNA levels in normal human
melanocytes (unpublished observations).
It has been reported that ASP alone inhibits melanin
formation in melan-a cells, B16 mouse melanoma cells and
normal human epidermal melanocytes (Hunt and Thody,
1995). In those experiments when ASP and a -MSH were
concomitantly used at equal concentrations, ASP failed to
antagonize the melanogenic effect of a -MSH. This result is not
surprising, as in competition assays, the antagonist should be
used at 10-100-fold higher concentration than the agonist in
order to displace it effectively from the receptor. In another
study, using mouse B16 melanoma cells, it was found that ASP
at relatively higher concentrations inhibited a -MSH-induced
melanin production, and additionally abrogated the stimulatory
effects of forskolin and cholera toxin (Siegrist et al., 1997). An
important observation was reported in that study, namely that
B16 G4F cells that lack detectable MC1R expression failed to
respond to ASP. The sum of these results suggested that ASP
acts as a competitive inhibitor of a -MSH, and that expression
of the MC1R is required for melanocytes to respond to ASP.
Those results were obtained using malignant melanoma cells,
and thus did not resolve the issue of whether or not ASP acts
on normal mammalian melanocytes exclusively by binding to
the MC1R, or if ASP additionally binds to another receptor that
is as yet unknown. Using normal human epidermal
melanocytes, we previously found that they responded to ASP
with a reduction in basal tyrosinase activity and abrogation of
the mitogenic and melanogenic effects of a -MSH, forskolin
and dibutyryl cAMP (Suzuki et al., 1997). We also found that
ASP displaced 125I-NDP-a -MSH from the human MC1R. The
ability of ASP to antagonize effectors downstream from the
MC1R in mouse melanoma cells and normal human
melanocytes is difficult to explain. One speculation is that
binding of ASP to the MC1R may stimulate a signaling
pathway that blocks the activation of cAMP-dependent targets.
In the present study, we relied on the use of melanocytes
derived from three congenic mice strains that differ only in the
Mc1r alleles expressed. Comparison of the responses of E+/E+
melanocytes to those of e/e and Eso/Eso revealed that only
E+/E+ melanocytes expressing wild-type MC1R responded to
a -MSH with a significant stimulation of cAMP formation and
tyrosinase activity, and to ASP with a reduction in basal
tyrosinase activity and abrogation of the effects of a -MSH on
tyrosinase activity and cAMP levels (Fig. 1 A-C; Table 1). The
inhibitory effect of ASP on tyrosinase activity in control
melanocytes may be due to the antagonism by ASP of
melanocortins that are present in fetal calf serum in the growth
medium, or that are synthesized by the melanocytes
themselves. Alternatively, binding of ASP to the MC1R may
inhibit one of the pathways that regulate tyrosinase activity,
such as the protein kinase C pathway (Park et al., 1993). This
latter possibility explains the lack of reduction of cAMP levels
in melanocytes treated only with ASP (Table 1). The
melanogenic response of E+/E+ melanocytes to a -MSH
also included an increase in the protein levels of tyrosinase,
TRP1 and TRP2 (Fig. 3A-C). These effects were completely
abrogated by concomitant treatment with ASP. However,
neither e/e melanocytes with loss-of-function mutation in the
Mc1r gene, nor Eso/Eso melanocytes with a constitutively active
MC1R responded significantly to either a -MSH or ASP. The
small increase in tyrosinase, TRP1 and TRP2 levels in e/e
melanocytes after a -MSH treatment might be attributed to
residual activity of the mutant MC1R.
Unlike e/e or Eso/Eso melanocytes, E+/E+ melanocytes
responded to a -MSH with extensive increase in dendrite
formation and in the size of melanocytes (Fig. 2C). Dendrite
extension in response to a -MSH has been described previously
in human melanocytes and was attributed to increased actin
stress fibers and adhesion to extracellular components (Abdel-
Malek et al., 1995; Scott et al., 1997). Human melanocytes
exhibited the same morphological changes after treatment with
dibutyryl cAMP, suggesting that these alterations are mediated
by activation of the cAMP pathway. Treatment of E+/E+
melanocytes with ASP reduced their size and the extent of their
dendricity, and completely reversed the morphological effect
of a -MSH (Fig. 2E).
Among the above three different mouse melanocyte cultures,
e/e melanocytes were the slowest in their proliferation, and
became extremely pigmented, owing to accumulation of
melanin in response to continuous exposure to dibutyryl cAMP
in the growth medium. On several occasions, e/e melanocytes
died in culture after becoming extensively pigmented, possibly
owing to accumulation of cytotoxic melanin by-products that
were not diluted by cell division. There is convincing evidence
that a -MSH counteracts oxidative stress in epidermal cells
(Haycock et al., 2000). Thus, it is plausible that e/e
melanocytes have increased sensitivity to oxidative DNA
damage, owing to their inability to respond to a -MSH. We
speculate that the observed cytotoxicity of those melanocytes
is due to the loss-of-function mutation that possibly acts in a
dominant negative fashion.
The significance of our current results is that they are based
on the use of primary cultures of congenic mouse melanocytes
that express wild-type MC1R or naturally occurring mutations
in the Mc1r. Using these melanocytes, rather than transformed
melanoma cells (as used in previous studies by other
investigators; Siegrist et al., 1997), we provide conclusive
biochemical evidence that the MC1R is the principal mediator
of the biological effects of ASP. This conclusion is
corroborated by previous findings that Chinchilla mice that
express the e mutation but have a normal agouti gene (A/A,
MC1Re/MC1Re, cch/cch) have the same coat color as Chinchilla
mice with the e mutation and the lethal yellow mutation in the
agouti gene (Ay/-, MC1Re/MC1Re, cch/cch) that results in
increased and ectopic expression of ASP (Ollmann et al.,
1998). The latter observation suggests that expression of a non-
functional MC1R renders melanocytes unresponsive to ASP,
even when ASP is expressed at abnormally high levels. The
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results obtained using mice strains that harbor mutations at the
extension and/or agouti locus provide strong support for the
notion that the MC1R is the key mediator of the effects of
melanotropins and ASP on mammalian melanocytes.
In mice, eumelanin and pheomelanin synthesis in follicular
melanocytes is primarily determined by MC1R function and
proper temporal expression of ASP (Silvers, 1979; Tamate and
Takeuchi, 1984). In humans, several population studies have
concluded that specific mutations in Mc1r are strongly associated
with red hair (i.e. pheomelanogenic) phenotype (Valverde et al.,
1995; Smith et al., 1998). Additionally, mutations that disrupt the
normal expression of proopiomelanocortin, the precursor peptide
for melanotropins and other bioactive peptides, result in red hair
and significant metabolic dysfunctions (Krude et al., 1998). So
far, no mutations in the human agouti gene have been identified,
and the regulation of ASP expression in humans remains elusive.
The results hereby presented take us a significant step forward in
understanding the signaling pathway of ASP. Further studies will
be aimed at identifying the exact binding site of ASP on the
MC1R and the second messengers involved in the signaling
pathway that leads to the biological effects of ASP.
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